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Poxviruses encode up to four different soluble TNF receptors, named cytokine response
modifier B (CrmB), CrmC, CrmD and CrmE. These proteins mimic the extracellular domain of
the cellular TNF receptors to bind and inhibit the activity of TNF and, in some cases, other TNF
superfamily ligands. Most of these ligands are released after the enzymic cleavage of a
membrane precursor. However, transmembrane TNF (tmTNF) is not only a precursor of soluble
TNF but also exerts specific pro-inflammatory and immunological activities. Here, we report that
viral TNF receptors bound and inhibited tmTNF and describe some interesting differences in
their activity against the soluble cytokine. Thus, CrmE, which does not inhibit mouse soluble
TNF, could block murine tmTNF-induced cytotoxicity. We propose that this anti-tmTNF effect
should be taken into consideration when assessing the role of viral TNF decoy receptors in the
pathogenesis of poxvirus.
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Poxviruses have evolved multiple mechanisms to evade the
host immune response, including the mimicry of cytokines
and their receptors (Alcami, 2003). A well-conserved strat-
egy is the expression of viral TNF receptors (vTNFRs),
secreted viral proteins that bind cytokines of the TNF
superfamily (TNFSF), inhibiting their biological activities
(Alejo et al., 2011). Four different TNF inhibitors are
included in the vTNFR family: cytokine response modifier
B (CrmB), CrmC, CrmD and CrmE. These vTNFRs have
been identified as TNF only, for CrmE and CrmC (Reading
et al., 2002; Saraiva & Alcami, 2001; Smith et al., 1996), or
as TNF and lymphotoxin a (LTa) inhibitors, for CrmB and
CrmD (Hu et al., 1994; Loparev et al., 1998). In addition,
we recently identified LTb as a new ligand for CrmD and
CrmB (Pontejo et al., 2015). Importantly, CrmB and
CrmD, but not CrmC and CrmE, contain an extended C-
terminal chemokine-binding domain termed SECRET
(Alejo et al., 2006). Previous data support a role of vTNFRs
in poxvirus pathogenesis. Using an intranasal mouse model
of recombinant vaccinia virus (VACV), Reading et al.
(2002) demonstrated that CrmB, CrmC and CrmE enhanced
VACV virulence. Similarly, a cowpox virus (CPXV) deficient
in CrmB but competent for other vTNFRs showed an
increased LD50 in a mouse intracranial infection model
(Palumbo et al., 1994). Finally, M-T2, the TNF inhibitor
encoded by the leporipoxvirus myxoma virus and homologue
to the orthopoxvirus vTNFRs, was shown to be required for a
fully symptomatic infection in rabbits (Upton et al., 1991).
The contribution of vTNFRs to poxvirus pathogenesis
suggests that their target ligands, TNF, LTa and LTb,
may play important roles in the antiviral response. TNF
and LTa share the cellular TNF receptors 1 and 2 (TNFR1
and TNFR2), while LTb signals through a distinct receptor,
LTbR (Aggarwal, 2003; Crowe et al., 1994). TNF and LTb,
but not LTa, like other TNFSF ligands, are first expressed
as transmembrane cytokines (Aggarwal, 2003). These mem-
brane ligands can be processed by a metalloproteinase to
release the soluble cytokines. Thus, transmembrane TNF
(tmTNF) is cleaved by the TNF-a converting enzyme releas-
ing the soluble TNF (sTNF) to act at remote sites (Black
et al., 1997). However, tmTNF can act locally and mediate
pro-inflammatory and immunological activities by itself
(Perez et al., 1990). While some of these tmTNF biological
activities overlap with those of sTNF, it has been shown
that tmTNF can mediate specific and distinct effects in
vitro and in vivo (Mueller et al., 1999), e.g. tmTNF has
been shown to be sufficient to induce arthritis (Georgo-
poulos et al., 1996). More importantly, tmTNF is a key
mediator of the defence against different pathogens. For
instance, transgenic mice expressing a non-cleavable form
of TNF are able to mount efficient immune responses
against bacterial infections such as Listeria monocytogenes,
Mycobacterium bovis and Mycobacterium tuberculosis
(Olleros et al., 2002, 2005; Torres et al., 2005). Similarly,
tmTNF has been shown to be sufficient to eliminate parasitic
infections of Leishmania major and Trichinella spiralis
3Present address: National Institute of Allergies and Infectious Diseases
(NIAID-NIH), Bethesda, MD 20892, USA.
Journal of General Virology (2015), 96, 3118–3123 DOI 10.1099/jgv.0.000255
000255 G 2015 The Authors Printed in Great Britain3118
Downloaded from www.microbiologyresearch.org by
IP:  150.244.206.36
On: Tue, 15 Nov 2016 08:13:50
(Allenbach et al., 2008; Ierna et al., 2009). However, the role
of tmTNF in the antiviral response remains poorly under-
stood. Although sTNF, but not tmTNF, is required to
limit the immunopathology upon influenza infection, no
differences were found in control of the viral burden
(DeBerge et al., 2014). By contrast, tmTNF-expressing cells
induce cell death of human immunodeficiency virus-
infected CD4 cells in vitro (Lazdins et al., 1997).
These differential activities between sTNF and tmTNF are
thought to arise from differences in their molecular prop-
erties. While both TNF forms interact with TNFR1 and
TNFR2, TNFR1 dominates the sTNF-induced intracellular
signalling, whereas TNFR2 is thought to act as a mere bind-
ing partner to increase the sTNF concentration on the cell
surface and pass the ligand to TNFR1 (Lu et al., 2001).
However, tmTNF can signal through both receptors,
which makes tmTNF the main activating ligand of TNFR2
(Grell et al., 1995). As TNFR1 and TNFR2 induce different
signalling cascades (Cabal-Hierro & Lazo, 2012), this could
explain the different biological activities found between
sTNF and tmTNF.
Poxvirus-encoded vTNFRs mimic the ligand binding
domain of cellular TNFRs, comprised of four repetitions
of cysteine-rich domains (CRDs). The CrmE structure
revealed that vTNFRs are more similar to TNFR2 than to
TNFR1 (Graham et al., 2007). This suggests that, despite
being identified as inhibitors of sTNF, tmTNF could be
one of the main targets of vTNFRs in vivo. Although
Smith et al. (1996) showed that CrmC binds mouse
tmTNF, its effect on biological activity was not addressed
and no further efforts have been reported in this regard.
Therefore, we decided to investigate whether other vTNFRs
can interact with tmTNF and if this interaction was able to
block the tmTNF-induced cytotoxicity.
vTNFRs are differentially expressed among poxvirus
species. Variola virus (VARV), the causative agent of small-
pox, and ectromelia virus (ECTV), which causes mousepox
in mice, express only one vTNFR, CrmB or CrmD, respect-
ively (Fenner, 1993; Mavian et al., 2014; Ribas et al., 2003).
However, CPXV strains express three to four different
vTNFRs (Alzhanova & Fru¨h, 2010). We recently defined
and compared the inhibitory and affinity properties of all
these vTNFRs for their soluble TNFSF ligands (Pontejo
et al., 2015). Here, we tested the tmTNF binding and block-
ing ability of ECTV CrmD, VARV CrmB, CrmE from the
CPXV strain Elephantpox and the three vTNFRs expressed
by the CPXV strain Brighton Red, CrmB, CrmC and
CrmD. All these genes were cloned in frame with a C-
terminal V5-His tag for their expression using recombinant
baculoviruses and purified as described previously (Pontejo
et al., 2015).
We first analysed whether vTNFRs were able to interact
with tmTNF. To this end, the binding of recombinant
vTNFRs to the surface of CHO-745 cells transfected or
not with human TNF was assessed by FACS. To guarantee
that the expressed TNF was retained on the cell surface,
cells were transfected with pSP23, a pcDNA3.1 plasmid
encoding a non-cleavable human TNF. The expression of
tmTNF was confirmed using an anti-human TNF antibody
(Fig. 1a). First, pSP23- and mock-transfected cells were
incubated with ECTV CrmD. As shown in Fig. 1(b),
CrmD was detected only on the surface of pSP23-trans-
fected cells. The cell staining level achieved with CrmD
was similar to the staining with the specific anti-human
TNF antibody in Fig. 1(a), suggesting that CrmD bound
to tmTNF-expressing cells. To confirm the specificity of
this binding, we assayed the binding of the two CrmD
domains, CRDs and SECRET, separately. These two
domains were expressed and purified using the same clon-
ing strategy and conditions applied to the full-length
vTNFRs. The TNF-binding domain CRDs, but not the
chemokine-binding domain SECRET, was detected on the
surface of pSP23-transfected cells, suggesting that the
observed binding of CrmD was mediated by tmTNF. For
subsequent experiments, the SECRET protein was therefore
included as a negative control. Next, we assayed the binding
of all the other vTNFRs and, as shown in Fig. 1(c), all were
detected on the cell surface when incubated with tmTNF-
expressing cells but not with mock-transfected cells. These
results demonstrated that vTNFRs interact with tmTNF.
The summary of the mean fluorescent intensities presented
in Fig. 1(d) shows that CPXV CrmC was the vTNFR with
the lowest tmTNF binding capacity, which agrees with the
lower affinity for human sTNF (VARV CrmB, KD 0.28 nM;
ECTV CrmD, KD 0.41 nM; CPXV CrmC, KD 2.42 nM) as
reported previously by us (Pontejo et al., 2015).
We investigated whether this binding of vTNFRs to tmTNF
was able to block the biological activity of tmTNF. For this,
we performed a cytotoxicity assay where the cell death of a
TNF-susceptible cell line, L929, was induced by co-cultiva-
tion with tmTNF-bearing cells. Because human tmTNF-
transfected cells did not display a consistent killing effect
towards susceptible cells, we used the mouse cell line
RAW 264.7 upon tmTNF induction with lipopolysacchar-
ide (LPS) following the protocol outlined in Fig. 2(a) and
adapted from published methods (Monastra et al., 1996).
The LPS-stimulated RAW 264.7 cells induced cytotoxicity
of L929 cells when co-cultivated at a 5 : 1 cell number
ratio (control, +LPS) (Fig. 2b). This L929 cell death was
mediated exclusively by TNF, as cells were protected
when LPS-induced RAW 264.7 cells were pre-incubated
with a soluble TNF receptor (hTNFR2, +LPS) or a TNF
neutralizing antibody (anti-TNF, +LPS) (Fig. 2b). The
protein hTNFR2 was purified as described previously
(Pontejo et al., 2015). To check that this cytotoxicity was
not induced by remaining traces of sTNF in the fixed
RAW 264.7 cell preparation, an equivalent cell volume of
supernatant from fixed LPS-induced RAW 264.7 cells
after the PBS washes was added to L929 cells and, as
expected, no cytotoxic effect was detected (medium,
+LPS) (Fig. 2b). Under these conditions, increasing con-
centrations of recombinant vTNFRs were incubated with
fixed LPS-activated RAW 264.7 cells before co-cultivation
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Fig. 1. vTNFRs bind human tmTNF. (a) FACS detection with an FITC-conjugated anti-TNF antibody (R&D) of human TNF
expression after transfection of CHO-745 cells with pSP23 using Fugene HD (Promega). pSP23 was generated after dele-
tion of the TNF-a converting enzyme cleavage site (77VRSSSRTPSDKP88) in the human TNF-pcDNA3.1 plasmid with the
primers hTNF del77-88 (59-CCTCTGGCCCAGGCAGTAGCCCATGTTGTA-39) and hTNF del77-88 antisense (59-TACAA-
CATGGGCTACTGCCTGGGCCAGAGG-39) using a QuikChange Lightning Site-Directed mutagenesis kit (Agilent Technol-
ogies). Grey shading, mock-transfected cells; dotted line, isotype control; solid line, pSP23-transfected cells. (b) FACS
analysis of the interaction of ECTV CrmD full-length, CRDs and SECRET domain with mock-transfected (grey shading) and
pSP23-transfected (solid line) cells. (c) FACS analysis of the binding of vTNFRs: VARV CrmB, and CPXV, CrmB, CrmC,
CrmD and CrmE to mock-transfected (grey shading) and pSP23-transfected (solid line) CHO-745 cells. In (b) and (c),
recombinant proteins were incubated on ice at 100 nM with 36105 mock- and pSP23-transfected cells for 30 min before
three PBS washes to remove unbound protein. Proteins were detected on the cell surface with a mouse anti-V5-His antibody
(Qiagen) followed by an anti-mouse Alexa Fluor 488-conjugated secondary antibody (Life Technologies). The fluorescence
histograms for 10000 events analysed using FlowJo 7.5 software (Treestar) are depicted. Results are representative of three
independent experiments. (d) Summary of the binding of recombinant proteins to pSP23-transfected cells. The mean fluor-
escence intensity (MFI) of the protein incubation with mock-transfected cells was subtracted from the corresponding pSP23-
transfected MFI. Data are represented as mean percentage¡SD of ECTV CrmD MFI of three independent experiments.
(Student’s t-test: *P,0.05, **P,0.01, ***P,0.001).
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with L929 cells. The SECRET domain from ECTV CrmD
was included as a negative control (Fig. 2c). We found
that CrmB orthologues ECTV CrmD and CrmC were effi-
cient inhibitors of tmTNF-induced cytotoxicity, as only
0.125 mg ml21 was sufficient to reach or exceed a 50% sur-
vival level (Fig. 2c). The CrmD orthologue of CPXV was a
weaker inhibitor as 1 mg ml21 was required to protect 50%
of the cells (Fig. 2c). This weak inhibition of mouse tmTNF
by CPXV CrmD agrees with its lower ability to inhibit
murine sTNF than other vTNFRs (Pontejo et al., 2015).
Strikingly, CrmE prevented the killing effect of mouse
tmTNF. CrmE protected 50% of L929 cells at 0.25 mg
ml21, being even more efficient than CPXV CrmD (Fig. 2c).
We and others have shown that CrmE is a specific human
TNF inhibitor (Pontejo et al., 2015; Reading et al., 2002;
Saraiva & Alcami, 2001). Despite binding mouse sTNF with
high affinity (KD 0.26 nM), CrmE does not inhibit the
mouse sTNF-mediated cytotoxicity. However, here we
showed that CrmE was able to block the biological activity of
murine tmTNF. Therefore, in the mouse host, CrmE would
inhibit tmTNF in a specific way. Reading et al. (2002)
showed that CrmE surprisingly enhanced the virulence of
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Fig. 2. vTNFRs block murine tmTNF-induced cytotoxicity. (a) Outline of the tmTNF-mediated cytotoxicity assay protocol.
RAW 264.7 cells were stimulated for 5 h with 500 ng LPS ml21 (E. coli strain O26 :B6; Sigma) to induce TNF. Sub-
sequently, cells were fixed with 1% paraformaldehyde (PFA) at room temperature for 15 min and washed profusely with PBS
before being added to L929 cells in a 5 : 1 (RAW 264.7 : L929) cell number ratio. (b) L929 cell survival after addition of acti-
vated (+LPS) and non-activated (2LPS) RAW 264.7 cells, incubated or not (control) with a TNF neutralizing antibody (anti-
TNF) or a soluble human TNF receptor (hTNFR2). In the Medium column, an equivalent cell volume of supernatant from fixed
activated RAW264.7 cells was incubated with L929 cells. (c) Inhibition of the activated RAW 264.7-induced cytotoxicity of
L929 cells by increasing concentrations of purified recombinant vTNFRs and SECRET protein. In (b) and (c), fixed RAW
264.7 cells were incubated in 100 ml Dulbecco’s Modified Eagle Medium (DMEM) with 2% FCS with a TNF neutralizing anti-
body or increasing amounts (0–1 mg ml21) of recombinant proteins for 30 min at room temperature. RAW 264.7 cells were
then added to L929 cells on 96-well plates in the presence of 4 mg actinomycin D (Sigma) ml21. Plates were incubated at
37 8C during 18 h and cell viability was determined by the CellTiter Aqueous One Solution kit (Promega). Values were nor-
malized with the absorbance value at 492 nm (A492) recorded from samples containing only RAW 264.7 cells and these
were set to zero. Data are represented as the percentage relative to the A492 value in the absence of RAW264.7 cells.
Means¡SD of triplicate samples of three representative experiments are shown in (b).
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the VACV vTNFR-deficient strain Western Reserve in an
intranasal mouse model. One of the authors’ hypotheses for
this phenotype was that CrmE could be inhibiting a different
TNFSF ligand. However, binding assays with many other
TNFSF cytokines did not identify additional ligands for
CrmE (Saraiva &Alcami, 2001).We propose that the observed
CrmE contribution to VACV virulence in mice may be due
to its ability to block mouse tmTNF.
Previous data suggest that the molecular mechanisms that
drive the receptor binding and signalling of sTNF are not
completely conserved in tmTNF. Thus, point mutations
of Arg31, Tyr87 and Tyr119, which are known to be key resi-
dues for the sTNF biological activity (Zhang et al., 1992),
have little or no effect in tmTNF (Zheng et al., 2009).
Similarly, some mutations in the leader sequence, which
anchors tmTNF to the cell membrane and is absent in
sTNF, have deleterious effects on tmTNF bioactivity
(Zheng et al., 2009). These data suggest that the molecular
structures of sTNF and tmTNF may be different. Therefore,
it cannot be presumed that a sTNF inhibitor will block
tmTNF and vice versa. One example is our finding that
CrmE inhibited mouse tmTNF but not sTNF. There are
two possible molecular explanations for this observation:
(i) the ligand residues in contact with CrmE are different
in tmTNF and sTNF; or (ii) the ligand residues in contact
with CrmE are the same in sTNF and tmTNF, but these
are key residues for the biological activity of tmTNF only.
Further molecular studies will be needed to distinguish
between these two possibilities.
Here, we reported that vTNFRs inhibits tmTNF, adding a
new ligand to the TNFSF cytokines known to be blocked
by vTNFRs (Fig. 3). It has been shown that the tmTNF–
TNFR interaction may induce cell signalling not only
within the receptor-bearing cells but also within the
tmTNF-expressing cells, a phenomenon known as ‘reverse
signalling’ (Eissner et al., 2004). Although the biological
effects of this signalling are not fully understood, some
contributions of the reverse signalling in tmTNF-bearing
T-cells, monocytes, macrophages and NK cells have been
described (Horiuchi et al., 2010). It will be interesting to
evaluate whether the vTNFR–tmTNF interaction can trig-
ger intracellular signals through reverse signalling and
how this signalling modulates the immune response in
poxvirus infections.
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